title: Thyroid cancer in children: the Royal Marsden Hospital experience.
abstract: The first child with well-differentiated thyroid cancer treated at the Royal Marsden Hospital presented in 1917. Since that time 30 children under the age of 16 years have been treated over a period during which many new treatments have been introduced. We have reviewed their management and outcome. The median follow-up is 22.5 years (range: 1-66). The median time to recurrence was 7 years (range: 2-44). There were events up to 44 years after presentation. The risk of recurrence was higher in children aged 10 years or younger [HR 3.45, 95% CI (1.04-11.11) P = 0.03]. Thyroid stimulating hormone (TSH) suppression was the only intervention to be shown to reduce the recurrence rate [HR 11, 95% CI (2.27-50) P = 0.0003]. The median overall survival is 53 years. The only presenting feature predictive of poorer survival was the presence of metastases (HR 28.96, 95% CI 2.51-334, P < 0.001). Patients who developed recurrence had a higher risk of death (HR 9.90, 95% CI 0.98-100, P = 0.02) and a shorter median survival of 30 years. No therapeutic intervention could be shown statistically to impact on survival. Our recommendation for treatment is total or near-total thyroidectomy for all patients and radioiodine ablation for all except those with early T stage node-negative disease aged over 10 years. Modified neck dissection is recommended for children with clinically positive neck nodes and TSH suppression for all. Follow-up with serial thyroglobulin measurement should be lifelong.
authors.affiliation: Department of Clinical Oncology, Royal Marsden Hospital, London, UK. david.landau@rmh.nthames.nhs.uk
authors.forename: D
authors.initials: D
authors.lastname: Landau
authors.forename: L
authors.initials: L
authors.lastname: Vini
authors.forename: R
authors.initials: R
authors.lastname: A'Hern
authors.forename: C
authors.initials: C
authors.lastname: Harmer
mesh_terms: D000293:Adolescent; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D012307:Risk Factors; D015996:Survival Rate; D013964:Thyroid Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery; D013965:Thyroidectomy / Q000379:methods / Q000706:statistics & numerical data; D013972:Thyrotropin / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
chemical_list: D013972:Thyrotropin